Ashorne Mahenthiran

Mr. Ashorne Mahenthiran

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Journal of Urology
Verified
Journal Article
Closed access
ITIsamu Tachibana
Isamu Tachibana
EFEthan L. Ferguson
Ethan L. Ferguson
AMAshorne Mahenthiran
Ashorne Mahenthiran
JNJay P. Natarajan
Jay P. Natarajan
TMTimothy A. Masterson
Timothy A. Masterson
CSChandru P. Sundaram
Chandru P. Sundaram
Purpose:Coronavirus Disease 2019 (COVID-19) is a global pandemic affecting hospital systems and the availability of resources for surgical procedures. Our aim is to provide guidance for urologists ...

27 March 2023 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
MSMohammad R. Siddiqui
Mohammad R. Siddiqui
ELEric V. Li
Eric V. Li
SKSai K. S. R. Kumar
Sai K. S. R. Kumar
ABAnna Busza
Anna Busza
JLJasmine S. Lin
Jasmine S. Lin
ARAshley E. Ross
Ashley E. Ross

12 May 2022 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
MSMohammad R. Siddiqui
Mohammad R. Siddiqui
BABrandon Ansbro
Brandon Ansbro
PSParth V. Shah
Parth V. Shah
JAJonathan A. Aguiar
Jonathan A. Aguiar
ELEric V. Li
Eric V. Li
ARAshley E. Ross
Ashley E. Ross

24 February 2020 in Cancers
Verified
Journal Article
Open access
PDF file
SNSonali Nayak
Sonali Nayak
AMAshorne Mahenthiran
Ashorne Mahenthiran
YYYONGYONG YANG
YONGYONG YANG
MMMark McClendon
Mark McClendon
BMBarbara Mania-Farnell
Barbara Mania-Farnell
GXGuifa Xi
Guifa Xi
Malignant gliomas are heterogeneous neoplasms. Glioma stem-like cells (GSCs) are undifferentiated and self-renewing cells that develop and maintain these tumors. These cells are the main population that resist current therapies. Genomic and epigenomic analyses has identified various molecular subtypes. Bone morphogenetic protein 4 (BMP4) reduces the number of GSCs through differentiation and induction of apoptosis, thus increasing therapeutic sensitivity. However, the short half-life of BMP4 impedes its clinical application. We previously reviewed BMP4 signaling in central nervous system development and glioma tumorigenesis and its potential as a treatment target in human gliomas. Recent advances in understanding both adult and pediatric malignant gliomas highlight critical roles of BMP4 signaling pathways in the regulation of tumor biology, and indicates its potential as a therapeutic molecule. Furthermore, significant progress has been made on synthesizing BMP4 biocompatible delivery materials, which can bind to and markedly extend BMP4 half-life. Here, we review current research associated with BMP4 in brain tumors, with an emphasis on pediatric malignant gliomas. We also summarize BMP4 delivery strategies, highlighting biocompatible BMP4 binding peptide amphiphile nanostructures as promising novel delivery platforms for treatment of these devastating tumors.

5 April 2022 in Journal of Surgical Research
Verified
Journal Article
Closed access
AMAshorne Mahenthiran
Ashorne Mahenthiran
BBBrian C. Brajcich
Brian C. Brajcich
SKSamuel Kim
Samuel Kim
ABAnkit Bharat
Ankit Bharat
DODavid D. Odell
David D. Odell

16 February 2020 in Preprints.org
Verified
Preprint
Open access
PDF file
SNSonali Nayak
Sonali Nayak
AMAshorne Mahenthiran
Ashorne Mahenthiran
YYYONGYONG YANG
YONGYONG YANG
MMMark McClendon
Mark McClendon
BMBarnara Mania-Farnell
Barnara Mania-Farnell
GXGuifa Xi
Guifa Xi
Malignant gliomas are heterogeneous neoplasms. Glioma stem-like cells (GSCs) are undifferentiated and self-renewing cells that develop and maintain these tumors. These cells are the main population that resist current therapies. Genomic and epigenomic analyses has identified various molecular subtypes. Bone morphogenetic protein 4 (BMP4) reduces the number of GSCs through differentiation and induction of apoptosis, thus increasing therapeutic sensitivity. However, the short half-life of BMP4 impedes its clinical application. We have previously reviewed BMP4 signaling in central nervous system development and glioma tumorigenesis and its’ potential as a treatment target in human gliomas. Recent advances in understanding both adult and pediatric malignant gliomas highlight critical roles of BMP4 signaling pathways in the regulation of tumor biology, and indicate its’ potential as a therapeutic molecule. Furthermore, significant progress has been made on synthesizing BMP4 biocompatible delivery materials, which can bind to and markedly extend BMP4 half-life. Here, we review current research associated with BMP4 in brain tumors, especially in pediatric malignant gliomas. We also summarize BMP4 delivery strategies, with a focus on biocompatible BMP4 binding peptide amphiphile nanostructures as promising novel delivery platforms for treatment of these devastating tumors.